Abbott Laboratories $ABT Shares Purchased by Clarius Group LLC

Clarius Group LLC raised its stake in shares of Abbott Laboratories (NYSE:ABT) by 4.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 11,920 shares of the healthcare product maker’s stock after buying an additional 552 shares during the quarter. Clarius Group LLC’s holdings in Abbott Laboratories were worth $1,621,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Quent Capital LLC grew its holdings in Abbott Laboratories by 13.1% during the 2nd quarter. Quent Capital LLC now owns 6,375 shares of the healthcare product maker’s stock valued at $867,000 after buying an additional 736 shares during the last quarter. NTV Asset Management LLC lifted its stake in shares of Abbott Laboratories by 0.3% during the 2nd quarter. NTV Asset Management LLC now owns 32,749 shares of the healthcare product maker’s stock worth $4,454,000 after purchasing an additional 99 shares during the period. QRG Capital Management Inc. lifted its stake in shares of Abbott Laboratories by 16.6% during the 2nd quarter. QRG Capital Management Inc. now owns 404,050 shares of the healthcare product maker’s stock worth $54,955,000 after purchasing an additional 57,569 shares during the period. Precedent Wealth Partners LLC lifted its stake in shares of Abbott Laboratories by 8.2% during the 2nd quarter. Precedent Wealth Partners LLC now owns 2,929 shares of the healthcare product maker’s stock worth $398,000 after purchasing an additional 221 shares during the period. Finally, Fairvoy Private Wealth LLC lifted its stake in shares of Abbott Laboratories by 1.3% during the 2nd quarter. Fairvoy Private Wealth LLC now owns 28,834 shares of the healthcare product maker’s stock worth $3,922,000 after purchasing an additional 359 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Buying and Selling

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the firm’s stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.46% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

ABT has been the topic of a number of recent analyst reports. Jefferies Financial Group raised Abbott Laboratories from a “hold” rating to a “buy” rating and increased their price target for the stock from $143.00 to $145.00 in a research note on Friday, July 18th. Mizuho increased their price target on Abbott Laboratories from $130.00 to $140.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 16th. Raymond James Financial reduced their price target on Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating on the stock in a research note on Friday, July 18th. BTIG Research cut their target price on Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating on the stock in a research report on Friday, July 18th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Abbott Laboratories in a research report on Saturday, September 27th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $145.39.

Abbott Laboratories Trading Up 1.1%

Shares of ABT opened at $134.49 on Friday. The stock’s fifty day simple moving average is $131.94 and its 200 day simple moving average is $131.36. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The firm has a market capitalization of $234.07 billion, a P/E ratio of 16.85, a price-to-earnings-growth ratio of 2.55 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The company had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. During the same period last year, the company posted $1.14 earnings per share. The firm’s revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, equities research analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be given a $0.59 dividend. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 annualized dividend and a yield of 1.8%. Abbott Laboratories’s dividend payout ratio (DPR) is 29.57%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.